Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 28, 2010

Premium

OncoMethylome Sciences this week appointed Melissa Thompson as vice president of regulatory affairs and quality assurance, and Christopher Thibodeau as vice president of commercial operations.

Thompson has provided consultative services to a number of pharmaceutical and biotech companies in the past, including Affymetrix, Signature Genomics, and Exonhit Therapeutics.

Thibodeau joins OncoMethylome from Agendia, where he was senior director of marketing. He held similar positions at Numira Biosciences, US Labs, and Ventana Medical.


Huron Technologies, a Waterloo, Canada-based digital pathology and microarray tools company, recently announced a new management team after Confocal acquired a controlling interest in the firm.

Savvas Chamberlain has been named acting CEO. Chamberlain founded imaging firm Dalsa in 1980 and served as its CEO until 2007. He now is chairman of its board. In addition to Chamberlain's appointment, Mike Panayi has been named chief financial officer; Audil Virk has been appointed chief operating officer; Savvas Damaskinos is now chief technology officer; and Ted Dixon has been appointed vice president of science and technology.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.